The Relative Strength (RS) Rating for Stryker moved into a higher percentile Thursday, as it got a lift from 69 to 72.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves. See if Stryker can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Stryker is building a flat base with a 398.20 entry. See if the stock can break out in volume at least 40% higher than normal.
Earnings grew 17% last quarter, up from 11% in the prior report. Revenue also increased, from 9% to 12%.
Stryker holds the No. 12 rank among its peers in the Medical-Products industry group. Globus Medical, Penumbra and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!